Thermo Fisher Scientific (TMO)
Health Care · Life Sciences Tools & Services · NYSE
A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
What Thermo Fisher Scientific does
Thermo Fisher Scientific is a global provider of analytical instruments, laboratory equipment, software, services, and consumables used in scientific research, healthcare, industrial, and safety applications. The company supports customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies. Its operations span the entire scientific lifecycle, from early-stage discovery and research to production and clinical diagnostics.
Themes: life sciences research tools, clinical diagnostics, bioprocessing infrastructure, laboratory automation, precision medicine support, pharmaceutical R&D enablement
Fundamentals
- Price$651.98 as of 2026-10-08 close
- Market cap$241.1B as of 2026-06-27 (share count; price 2026-10-08)
- 1-year return+21.6% 2025-10-08 close $536.19 → 2026-10-08 close $651.98
- P/E35.10 as of 2026-10-08
- Net margin+15.0% FY2025, SEC XBRL
- ROE+12.6% FY2025, SEC XBRL
- Debt / equity0.81 as of 2026-09-02
- Revenue growth (YoY)+7.2% as of 2026-09-02
- Revenue CAGR (3y)-0.3% SEC XBRL
- Beta0.77 as of 2026-09-02
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.3%; 14-year non-decreasing per-share dividend streak (SEC XBRL).
How TMO compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-02
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- indicated dividend yieldbottom 25% 72 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
TMO is not currently in any published Top 10 list. Its scores are below.
Top 10 score
54.9 #472 of 1,379 scored · #54 of 151 in Health Care
Trend 78th (a strong uptrend, with buyers in control) and capital return 75th (consecutive years of dividend increases 14 years, net share count bought back over the year 1.3); weakest is growth (31st, 3-year revenue CAGR -0.3%, revenue growth year over year 7.2%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, TMO's dividend was covered by reported results (earnings payout 9%, free-cash-flow payout 10%). This describes past coverage, not a forecast.
- Earnings payout9% dividends / net income
- Free-cash-flow payout10% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Thermo Fisher Scientific looks technically
Thermo Fisher Scientific (TMO) is trading 19.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative). It made a new 20-day high about 8 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 19.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +19.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $624.78 | $624.78 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $545.74 | $545.74 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 594.82. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal | 36 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 40, with buyers in control | 39.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 52, neither overbought (above 70) nor oversold (below 30) | 52.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($635.32 to $694.33) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 28.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 6 trading days ago (its momentum flipped negative) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $694.33 | $694.33 |
|---|---|---|
| From the 52-week high | it is 6.1% below its 52-week high (its highest price of the past year) | -6.1% |
| Above the 52-week low | it is 49.8% above its 52-week low (its lowest price of the past year) | +49.8% |
| Below the 52-week high | it is 6.1% below its highest point of the past year | 6.1% |
| Since a 20-day breakout | it made a new 20-day high about 8 trading days ago | 8 sessions |
| Since a 55-day breakout | it made a new 55-day high about 8 trading days ago | 8 sessions |
| All-time high | its highest closing price on record is $694.33 (set on 2026-10-06) | $694.33 |
| Given back of the 52-week move | over the past year its closes ranged ($438.34 to $679.61), and it has given back only a small part of its rise from last year’s low — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $522.78 to $530.51. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 11.4% |
| From the all-time high | it is 6.1% below its all-time high | -6.1% |
| Nearest price level | it is trading 3.0% above a support level at $632.61 — a price it turned at twice since 2026-01-06, most recently on 2026-08-27. Since 2024-10-08 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.0% |
| All-time low | its lowest closing price on record is $12.50 (set on 1999-04-09) | $12.50 |
| Above the all-time low | it is 5115.8% above its all-time low | +5,116% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $18.83 between its high and its low — about 2.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $18.83 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $619.72 and $694.98 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $619.72 – $657.35 – $694.98 |
| Typical daily range (% of price) | its price moves about 2.9% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.9% |
| Stretch from the 200-day average | it is trading 5.6 daily ranges above its 200-day average price (19.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.22× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.4% since the prior reading | +0.4% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.02 toward sell |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.7% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 51 sessions ago and has not traded back through the level it left behind at 559.53 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 3.6% gap down opened on 2026-07-21 has been "filled" 56 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 56 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.1 percentage points (the stock gained 8.1% while the market gained 1.0%) | +7.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 24.0 percentage points (the stock gained 27.8% while the market gained 3.8%) | +24.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 16.1 percentage points (the stock gained 33.6% while the market gained 17.5%) | +16.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 6.6 percentage points (the stock gained 21.6% while the market gained 15.0%) | +6.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 7.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.3% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +7.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $546.27 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +19.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-07-23 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $621.64 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +4.9% |
Rising wedge, bearish — broke down · entry $656.56 · 87 sessions in
Price levels it has turned at before
TMO last closed at $651.98 on 2026-10-08. Since 2024-10-08 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $632.61 | Support | 3.0% below the last close | turned there twice · 2026-01-06 to 2026-08-27 |
| $610.76 | Support | 6.3% below the last close | turned there twice · 2024-10-15 to 2025-01-30 |
| $595.70 | Support | 8.6% below the last close | turned there five times · 2025-11-13 to 2026-09-10 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $594.82.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $634.21 and $697.94 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 16 trading days, since 2026-09-17.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · beating the market · Printed a hammer candle after a decline · Trading above the Ichimoku cloud · Elliott wave 5 candidates | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.54 mean, 1=Strong Buy…5=Strong Sell) — 26 analysts
- Mean price target$655.73 range $520.00 – $780.00; median $650.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TMO
- Consensus EPS estimate$6.41 next reporting period, as of 2026-10-06
- Estimate change, 30 days+$0.0055 (+0.1%) from $6.40, on 2026-09-01, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High levels of debt from acquisitions and the need for ongoing successful integration of acquired businesses.","Intense global competition across diverse product lines and potential for pricing pressure.","Dependency on continued R&D spending by pharmaceutical, biotech, and academic customers."]
What changed in the latest 10-Q
AI-assisted comparison of TMO's 10-Q filed 2026-05-01 against the prior one filed 2025-10-31.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-01) references Private Securities Litigation Reform Act of 1995 in forward-looking statements disclaimer, whereas older filing (2025-10-31) references Section 21E of the Securities Exchange Act of 1934
- Newer filing adds structured bullet-point list of forward-looking statement topics: financial expectations, operational matters, market and competitive conditions, strategic actions, legal/regulatory/macroeconomic/geopolitical/public health/supply chain/technology/cybersecurity developments
- Newer filing specifies Risk Factors location as 'Annual Report on Form 10-K for the year ended December 31, 2025' versus older filing's 'December 31, 2024'
- Newer filing adds reference to Clario Holdings, Inc. acquisition on March 24, 2026 in Laboratory Products and Biopharma Services segment
- Newer filing reports Q1 2026 results (March 28, 2026) with revenues of $11,005M versus older filing's Q3 2025 results (September 27, 2025) with revenues of $11,122M
- Removed:
- Older filing (2025-10-31) included nine-month results data; newer filing (2026-05-01) contains only three-month results
- Older filing detailed third quarter 2025 market conditions and performance by segment; newer filing focuses on first quarter 2026 conditions
- Older filing included discussion of nine-month organic revenue growth and market performance; newer filing contains only Q1 2026 organic revenue data
- Reworded:
- Forward-looking statements identification changed from 'may be deemed to be forward-looking statements' (older) to 'should be considered forward-looking statements' (newer)
- Newer filing restructured forward-looking statement categories into explicit bullet points versus older filing's prose format with similar but differently organized content
- Older filing stated tariffs impact in narrative about margin changes; newer filing specifies 'tariffs and related foreign currency effects' as distinct factor in operating margin discussion
- Newer filing describes Q1 2026 margin decrease as 'largely offset by very strong productivity improvements' versus older filing's Q3 2025 description of margin increase 'due primarily to very strong productivity improvements, partially offset by' other factors
- Notes:
- The two filings report results for different quarters (Q1 2026 vs Q3 2025) and different reporting periods, making some comparisons reflect period-to-period changes rather than filing revisions
- Text appears truncated in older filing at 'GAAP operating income margin and ad', limiting full assessment of comparative discussion of operating margin drivers
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 93 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 93 sells ($62M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 94 sells ($62M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-31. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TMO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 32 matched disclosures for TMO from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding TMO as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 66,035,746
- Reported value $33,115,486,619
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TMO's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TMO had 5,019,933 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
TMO had 1.36% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.74 days to cover at the same settlement.
- Reported short interest (shares) 5,019,933
- Short interest (% of shares outstanding) 1.36%
- Prior settlement (shares) 5,690,588
- Reported change -11.79%
- Days to cover (reported) 2.74
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Danaher (DHR)
- Agilent Technologies (A)
- Waters Corporation (WAT)
- Bruker Corporation (BRKR)
- PerkinElmer (now Revvity) (RVTY)
- Bio-Rad Laboratories (BIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TMO vs…
Thermo Fisher Scientific is found in…
Frequently asked questions
What does Thermo Fisher Scientific (TMO) do?
Thermo Fisher Scientific is a global provider of analytical instruments, laboratory equipment, software, services, and consumables used in scientific research, healthcare, industrial, and safety applications. The company supports customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.
What sector is Thermo Fisher Scientific (TMO) in?
Thermo Fisher Scientific (TMO) is classified in the Health Care sector. Its industry is Life Sciences Tools & Services. It trades on NYSE.
Does TMO pay a dividend?
Yes — Thermo Fisher Scientific (TMO) pays a dividend, with an indicated yield of about 0.29% and 14-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-02). Informational only — not financial advice.
Who are Thermo Fisher Scientific's (TMO) competitors?
Notable peers of Thermo Fisher Scientific (TMO) include Danaher, Agilent Technologies, Waters Corporation, Bruker Corporation and PerkinElmer (now Revvity). This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in TMO?
Yes — we hold 32 matched STOCK Act disclosures for TMO from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Thermo Fisher Scientific (TMO) overbought or oversold right now?
Thermo Fisher Scientific (TMO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 52, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TMO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.